[ad_1]
The International Solidarity Clinical Trial, initiated by the World Health Organization (WHO), is designed to investigate potentially effective drugs for COVID-19. In Lithuania, it is carried out by the Santara Clinic of the Vilnius University Hospital together with the Kaunas Clinics of the Lithuanian University of Health Sciences.
According to the Ministry of Health, given that COVID-19 patients are willing to participate in this clinical trial and the number of subjects is approaching the maximum, the Santara Clinic of the Vilnius University Hospital, which coordinates the study in Lithuania, has announced his intention to modify the study and increase the number to 200.
Clinical trials have demonstrated the efficacy and safety of remdesivir, acalabrination, and interferon beta-1a compared to standard treatment for COVID-19. Subjects are randomly assigned to receive standard therapy or one of the study drugs.
This clinical trial was launched in Lithuania in May this year and is expected to continue until April 2021.
Originally a sample of 20 subjects was planned, now it has been increased to 100.
The premiums for the liability insurance of the principal investigators of the clinical trial “Solidarity” and the clients of the biomedical research, which is compulsory for all biomedical research in Lithuania, are paid by the Ministry of Health. The expenses for the services of this insurance currently amount to 15 thousand. euros.
[ad_2]
